News

ORBIT II, Diamondback 360, CSI, SCAI 2015, atherectomy

Cardiovascular Systems Inc. (CSI) featured two-year data from its ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system (OAS) in a late-breaking presentation at...

Boston Scientific, investors, cardiology, growth, expansion

Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth strategies at a meeting with the investment community May 1.

Medtronic, Euphora, SC, semicompliant balloon dilatation catheter, FDA, U.S.

Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance and U.S. launch of the Euphora Semicompliant Balloon Dilatation Catheter. Euphora is a pre-dilatation therapy used...

RaySafe i2 real-time dose monitoring, radiation dose monitoring, cath lab

Physicians and staff working in cath labs are constantly exposed to direct X-ray beams and scatter radiation. Traditionally cath lab staff wear radiation badges to record exposure, but these only...

Edward Diethrich, ORSIF, fluoroscopy, radiation, risks, documentary

The Organization for Occupational Safety in Interventional Fluoroscopy (ORSIF) announced the release of a new documentary film on the impact of chronic, low-level exposure to ionizing radiation on...

heart stent, OAP therapy, ACS, patients, PCNA, SCAI, medication, prescribed

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart...

Stellarex, Spectranetics, investment, BTK, peripheral artery disease

The Spectranetics Corporation announced it is accelerating investments in the Stellarex drug-coated balloon angioplasty (DCB) platform for treatment of below the knee (BTK) peripheral artery...

transmyocardial laser revascularization

Transmyocardial laser revascularization (TMLR or TMR) was introduced in the late 1990s as a method to offer relief to patients with incapacitating angina that were poor candidates for other...

Medtronic, SYMPLICITY AF, PVI, renal denervation, Arctic Front, Spyral, G3

Medtronic plc announced the start of a clinical study to determine whether paroxysmal and persistent atrial fibrillation (AF) can be treated with a combination of two ablation procedures targeting...

therapeutic hypothermia, children, cardiac arrest, treatment, temperature

A large-scale, multicenter study has shown that therapeutic hypothermia does not improve survival rates or reduce brain injury in infants and children with out-of-hospital cardiac arrest more than...

Thoratec, HeartMate II, ROADMAP

Thoratec Corp. announced results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients...

Vessix Renal Denervation System, REDUCE-HTN: REINFORCE, high blood pressure

Boston Scientific Corp. is taking a new approach to evaluate the performance of the Vessix Renal Denervation System, initiating a study to isolate the effects of the therapy in patients with...

Sunshine Heart, C-Pulse, COUNTER HF, FDA, review, pause, enrollment

Sunshine Heart Inc. announced that the U.S. Food and Drug Administration (FDA) has reviewed the company’s submission regarding the pause of the COUNTER HF U.S. pivotal study. The FDA has requested...

radiation dose monitoring, cath lab dose monitoring, Raysafe

It’s the invisible elephant in radiology — radiation exposure. As physicians, we know all too well that exposure to radiation should be limited to the least amount possible. We have all learned...

The Society for Cardiovascular Angiography and Interventions (SCAI) announced the following late-breaking clinical trials to be presented at its 2015 Scientific Sessions, May 6-9 in San Diego.

Brilinta, AstraZeneca, FDA, sNDA, PEGASUS-TIMI 54, new indication

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for Brilinta (ticagrelor) tablets for...

Medtronic, SWIFT PRIME, REVASCAT, Solitaire, stent thrombectomy, stroke

Two global trials have found that the addition of the Solitaire device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients...

Watchman, LAA, left atrial appendage

The long awaited U.S. Food and Drug Administration (FDA) approval of the first transcatheter left atrial appendage (LAA) occluder in March is seen by many cardiologists as a disruptive technology...

COR Medical Technologies (COR) announced that Gregg W. Stone, M.D. has been appointed to its Senior Editorial Board.

Boston Scientific, Eluvia, MAJESTIC trial, vascular stent, PAD

A key trial evaluating the Boston Scientific Eluvia drug-eluting vascular stent system met its primary endpoint, with more than 94 percent of the lesions treated for peripheral arterial disease (...